التفاصيل البيبلوغرافية
| العنوان: |
Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus. |
| المؤلفون: |
Fath, Maryam, Danne, Thomas, Biester, Torben, Erichsen, Lars, Kordonouri, Olga, Haahr, Hanne |
| المصدر: |
Pediatric Diabetes; Dec2017, Vol. 18 Issue 8, p903-910, 8p |
| مصطلحات موضوعية: |
ARGININE, CONFIDENCE intervals, TYPE 1 diabetes, PHARMACOKINETICS, BLIND experiment, INSULIN aspart |
| مستخلص: |
Background Faster-acting insulin aspart (faster aspart) is insulin aspart ( IAsp) in a new formulation with additional excipients (L-arginine and niacinamide). In adults, faster aspart provides faster onset and greater early exposure and action vs IAsp. Aim This randomized, double-blind, 2-period crossover trial investigated the pharmacological properties of faster aspart vs IAsp in 12 children (6-11 years), 13 adolescents (12-17 years), and 15 adults (18-64 years) with type 1 diabetes mellitus. Methods Subjects received 0.2 U/kg subcutaneous dosing (mean of 8.3, 12.8, and 15.6 U, respectively) immediately prior to a standardized meal (17.3 g carbohydrate/100 mL; amount adjusted by body weight). Results Consistently across age groups, onset of appearance occurred approximately twice-as-fast (5-7 minutes earlier) and early exposure ( AUCIAsp ,0-30min; area under the IAsp curve from 0 to 30 minutes) was greater (by 78%-147%) for faster aspart vs IAsp, with no treatment differences in total exposure ( AUCIAsp ,0-t) or maximum concentration ( Cmax). Two-hour postmeal plasma glucose excursion was reduced for faster aspart vs IAsp (although only reaching statistical significance in children). In accordance with the absolute dose administered for each age group, AUCIAsp ,0-t for faster aspart was lower in children (estimated ratio children/adults [95% confidence interval]: 0.59 [0.50;0.69], P < .001) and adolescents (0.78 [0.67;0.90], P = .002) vs adults. No age group differences were seen in Cmax (0.91 [0.70;1.17], P = .445, and 0.99 [0.77;1.26], P = .903). The age effect on AUCIAsp ,0-t and Cmax did not differ statistically significantly between treatments. Faster aspart and IAsp were well-tolerated. Conclusion The current findings in children and adolescents suggest a potential for faster aspart to improve postprandial glycemia over current rapid-acting insulins also in younger age groups. identifier: NCT02035371. [ABSTRACT FROM AUTHOR] |
|
Copyright of Pediatric Diabetes is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
